The expression of hypoxia-inducible factor 1α is a favorable independent prognostic factor in renal cell carcinoma

Clinical Cancer Research

Volumn 11, Issue 3, 2005, Pages 1129-1135

  Lidgren, Anders ^a   Hedberg, Ylva ^a   Grankvist, Kjell ^a   Rasmuson, Torgny ^a   Vasko, Janos ^a   Ljungberg, Börje ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY CORTEX; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS;

EID: 12944266844     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163:343-7.
2. Brieger J, Weidt EJ, Schirmacher P, Storkel S, Huber C, Decker HJ. Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors. J MoL Med 1999;77:505-10.
3. Ma X, Yang K, Lindblad P, Egevad L, Hemminki K. VHL gene alterations in renal cell carcinoma patients: novel hotspots or founder mutations and linkage disequilibrium. Oncogene 2001;20:5393-400.
4. Wiesener MS, Mûnchenhagen PM, Berger I, et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1α in clear cell renal carcinoma. Cancer 2001;61:5215-22.
5. Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002;20:1569-75.
6. Baba M, Hirai S, Yamada-Okabe H, et al. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of cyclinD1 expression through hypoxia-inducible factor. Oncogene 2003;22:2728-38.
7. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
8. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavourable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693-6.
9. Schindl M, Schoppmann SF, Samonigg H, et al. Overexpression of hypoxia-inducible factor 1α is associated with an unfavourable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002;8:1831-7.
10. Volm M, Koomagi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res 2000;20:1527-33.
11. Sobin LH, Fleming ID. TNM classification of malignant tumors. 5th ed. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-4.
12. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971;28:1165-77.
13. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131-3.
14. Wiesener MS, Turley H, Allen WE, et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1α. Blood 1998;92:2260-8.
15. Hedberg Y, Davoodi E, Roos G, Ljungberg B, Landberg G. Cyclin Dl expression in renal cell carcinoma. Int J Cancer 1999;84:268-72.
16. Dekernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978;120:148-52.
17. Giberti C, Oneto F, Martorana G, Rovida S, Carmignani G. Radical nephrectomy for renal cell carcinoma: long-term results and prognostic factors on a series of 328 cases. Eur Urol 1997;31:40-8.
18. Powell JD, Elshtein R, Forest DJ, Palladino MA. Stimulation of hypoxia-inducible factor-1α (HIF-1α) protein in the adult rat testis following ischemic injury occurs without an increase in HIF-1α messenger RNA expression. Biol Reprod 2002;67:995-1002.
19. Wang GL, Jiang B, Semenza GL. Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor 1. Biochem Biophys Res Comm 1995;216:669-75.
20. 2 sensing. Science 2001;292:464-8.
21. 2-regulated prolyl hydroxylation. Science 2001;292:468-72.
22. Richard DE, Berra E, Gothié E, Roux D, Pouysségur J. p42/p44 Mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activation of HIF-1. J Biol Chem 1999;274:32631-7.
23. Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J. MAPK signalling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 2003;278:14013-9.
24. Schraml P, Struckmann K, Hatz F, et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002;196:186-93.
25. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
26. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001;11:293-9.
27. Ohh M, Yauch RL, Lonergan KM, et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998;1:959-68.
28. Pause A, Lee S, Lonergan KM, Klausner RD. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit on serum withdrawal. Proc Natl Acad Sci U S A 1998;95:993-8.
29. Schoenfeld AR, Parris T, Eisenberger A, et al. The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis. Oncogene 2000;19:5851-7.
30. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237-46.
31. Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 2000;19:6297-305.
32. Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002;62:2957-61.
33. Na X, Wu G, Ryan CK, Schoen SR, di'Santagnese PA, Messing AM. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1α expression in renal cell carcinomas. J Urol 2003;170:588-92.
34. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000;19:5435-43.
35. Ljungberg B, Jacobsen J, Häggström-Rudolfsson S, Rasmuson T, Grankvist K. Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma. Urol Res 2003;31:335-40.
36. Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G, Ljungberg B. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004;93:297-302.
37. Blath RA, Mancilla-Jimenez R, Stanley RJ. Clinical comparison between vascular and avascular renal cell carcinoma. J Urol 1976; 115:514-9.
38. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
39. Mancilla-Jimenez R, Stanley RJ, Blath RA. Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases. Cancer 1976;38:2469-80.
40. Takahashi A, Sasaki H, Kim SJ, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994;54:4233-7.